Paxlovid Failed to Improve Long COVID Symptoms

A clinical trial found that the antiviral treatment provided no significant relief compared to a placebo.

Updated on Oct. 7, 2026 in COVID-19

Paxlovid Failed to Improve Long COVID Symptoms

Live Poll

Does medical research on Long COVID provide enough benefit to patients to justify the cost?

A large-scale study published on August 31, 2026, revealed that Paxlovid did not improve Long COVID symptoms in adults. The clinical trial showed that participants receiving the treatment fared no better than those given a placebo.

Why it matters

Researchers initiated the study to determine if an antiviral drug commonly used for acute COVID-19 could also treat the lingering effects of the virus. The results clarify the limited efficacy of existing antivirals for those experiencing long-term health complications.

The clinical trial included 959 adults across 69 sites in the United States. Participants underwent a treatment regimen of Paxlovid or a placebo for up to 25 days, with researchers monitoring symptoms over six months.

The players

Lancet Infectious Diseases

This peer-reviewed medical journal published the clinical trial results on August 31, 2026.

The details

Participants were randomized into three groups based on their primary symptoms, including cognitive issues, exercise intolerance, and blood pressure regulation. While the drug was well tolerated with few serious side effects, it failed to provide measurable benefits over the placebo.

Data collection for the clinical trial began in July 2023.
Data collection for the study concluded in March 2025.
Study results were published in Lancet Infectious Diseases on August 31, 2026.

The Big Picture

This study marks a significant finding within the broader effort to repurpose acute COVID-19 treatments for long-term symptom management. These results update the clinical understanding of the role antiviral medications play in post-viral care.

Patients currently seeking treatment for Long COVID should consult their healthcare providers, as this study suggests Paxlovid is not an effective solution for these specific symptoms. The findings reinforce that existing antivirals may not address the underlying causes of post-viral conditions.

The takeaway

While this study provides clarity on the limitations of current antiviral treatments, it also highlights the need for continued research into new therapeutic targets. Patients are encouraged to focus on evidence-based management strategies while the scientific community works to identify effective interventions.